Arcturus Therapeutics Holdings Inc. (ARCT) News
Filter ARCT News Items
ARCT News Results
|Loading, please wait...|
ARCT News Highlights
- For ARCT, its 30 day story count is now at 8.
- Over the past 7 days, the trend for ARCT's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
- The most mentioned tickers in articles about ARCT are MRNA, BNTX and FOLD.
Latest ARCT News From Around the Web
Below are the latest news stories about Arcturus Therapeutics Holdings Inc that investors may wish to consider to help them evaluate ARCT as an investment opportunity.
Citing data from its Phase 1/2 booster study for ARCT-154 and ARCT-165, Arcturus Therapeutics (ARCT) says that the companys self-amplifying mRNA vaccine candidates strongly
Arcturus Therapeutics Reports New Data Demonstrating Neutralizing Antibody Immune Response to the SARS-CoV-2 Omicron Variant from ARCT-154 and ARCT-165 Booster Clinical Trial
SAN DIEGO, January 25, 2022--Arcturus Reports Data Demonstrating Neutralizing Antibody Immune Response to the SARS-CoV-2 Omicron Variant from ARCT-154 and ARCT-165 Booster Trial
Arcturus Therapeutics (ARCT -9.1%) said data from ARCT-154 and ARCT-165 booster trial showed neutralizing antibody responses to SARS-CoV-2 and several variants. Full cohort data from the ARCT-154 (5 microgram) arm of an ongoing phase 1/2 booster study showed 30-fold increase in neutralizing antibody against SARS-CoV-2 after 15 days of booster...
Arcturus Therapeutics' COVID-19 Booster Clinical Trial Show Encouraging Neutralizing Antibody Responses
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) has announced updated data Phase 1/2 booster trial of ARCT-154 and ARCT-165, its investigational, self-amplifying mRNA COVID-19 vaccine candidates targeting the variants of concern. Data from the Phase 1/2 booster trial show that both ARCT-154 and ARCT-165, when administered as low-dose (5 mcg) boosters at least five months after Pfizer Inc's (NYSE: PFE) - BioNTech SE's (NASDAQ: BNTX) Comirnaty immunization, demonstrated robust antibody responses
Arcturus Therapeutics Updates Data from ARCT-154 and ARCT-165 Booster Clinical Trial Demonstrating Robust Neutralizing Antibody Responses to SARS-CoV-2 and Several Variants
SAN DIEGO, January 24, 2022--Arcturus Updates Data from ARCT-154 and ARCT-165 Booster Clinical Trial Demonstrating Robust Neutralizing Antibody Responses to SARS-CoV-2
SAN DIEGO, January 22, 2022--Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Krystal Biotech Appoints Jing Marantz, MD, PhD, MBA as Chief Business Officer and Rand Sutherland, MD, MPH to its Board of Directors
PITTSBURGH, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare disease, announced today the appointments of Jing Marantz as Chief Business Officer and Rand Sutherland as a new member of the Board of Directors. Dr. Marantz is an experienced biopharmaceutical industry executive who has held senior level positions in medical affairs, business development, and commercial strategy in multiple therapeutic areas, includin
While Arcturus Therapeutics Holdings (NASDAQ:ARCT) shareholders have made 872% in 3 years, increasing losses might now be front of mind as stock sheds 15% this week
It hasn't been the best quarter for Arcturus Therapeutics Holdings Inc. ( NASDAQ:ARCT ) shareholders, since the share...
New York, NY, based Investment company Orbimed Advisors Llc (Current Portfolio) buys Adagio Therapeutics Inc, Zimmer Biomet Holdings Inc, Biogen Inc, HCA Healthcare Inc, Erasca Inc, sells Prelude Therapeutics Inc, Aurinia Pharmaceuticals Inc, Ascendis Pharma A/S, Natera Inc, Anthem Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Orbimed Advisors Llc.
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)s share price gapped up before the market opened on Thursday . The stock had previously closed at $42.65, but opened at $43.86. Arcturus Therapeutics shares last traded at $42.00, with a volume of 2,855 shares. ARCT has been the subject of a number of analyst reports. Barclays decreased their price